NASDAQ : VVOS
Vivos Therapeutics, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 0.1138 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.29M |
| Enterprise Value | 13.02M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 18, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 20.12M |
| Shares Outstanding | 20.12M |
| Shares Change (YoY) | +72.97% |
| Shares Change (QoQ) | +20.83% |
| Owned by Insiders (%) | 5.11% |
| Owned by Institutions (%) | 16.05% |
| Float | 19.09M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.11 |
| Forward PS | 0.10 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.21 |
| Quick Ratio | 0.16 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.25 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -8,585.26% |
| Return on Assets (ROA) | -56.19% |
| Return on Invested Capital (ROIC) | -114.22% |
| Return on Capital Employed (ROCE) | -600.64% |
| Weighted Average Cost of Capital (WACC) | 17.77% |
| Revenue Per Employee | $77,415 |
| Profits Per Employee | -$94,281 |
| Employee Count | 270 |
| Asset Turnover | 0.83 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 6.30 |
| 52-Week Price Change | -95.74% |
| 50-Day Moving Average | 0.17 |
| 200-Day Moving Average | 0.74 |
| Relative Strength Index (RSI) | 27.64 |
| Average Volume (20 Days) | 8,178,043 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.36M |
| Short Previous Month | 2.86M |
| Short % of Shares Out | 11.72% |
| Short % of Float | 12.35% |
| Short Ratio (days to cover) | 0.45 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 20.90M |
| Gross Profit | 12.94M |
| Operating Income | -22.55M |
| Pretax Income | -25.63M |
| Net Income | -25.46M |
| EBITDA | -20.76M |
| EBIT | -22.55M |
| Loss Per Share | -$1.83 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.77M |
| Total Debt | 12.51M |
| Net Cash | -10.73M |
| Net Cash Per Share | -$0.53 |
| Equity (Book Value) | -3.99M |
| Book Value Per Share | -0.34 |
| Working Capital | -16.18M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -17.13M |
| Capital Expenditures | -1.88M |
| Depreciation & Amortization | 1.79M |
| Net Borrowing | 2.78M |
| Free Cash Flow | -19.01M |
| FCF Per Share | -$0.95 |
Margins
| Measure | Value |
|---|
| Gross Margin | 61.90% |
| Operating Margin | -107.90% |
| Pretax Margin | -122.61% |
| Profit Margin | -121.79% |
| EBITDA Margin | -99.33% |
| EBIT Margin | -107.90% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -72.97% |
| Shareholder Yield | n/a |
| Earnings Yield | -1,605.15% |
| FCF Yield | -830.47% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $1.93 |
| Price Target Difference | 1,591.56% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 27, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -10.65 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |